Pharmaceutical developers have chosen the Avacta Optim 1000 for preliminary formulation studies.
Synthon, which specialises in the development and manufacture of generic medicines, have chosen an Optim 1000 high throughput, micro-volume protein analysis system from Avacta for one of their latest projects.
Bas Kokke, Principal Scientist at Synthon, explained: “In recent years, our work has begun to focus on biopharmaceuticals and for that we needed different instrumentation to develop assays and study proteins in far more detail.
“As well as high throughput, a big advantage of the Optim 1000 is the small sample volume required – down to 9 µl – which is perfect for us. This is so important because we don’t want to make large quantities of each formulation when conducting fairly large, high throughput studies early on in a project.”
Guy de Roo, Lead Scientist at Synthon, added: “The Optim 1000 is now used for all formulation projects as an initial screening instrument and we regularly perform around 50 formulations for a given project, where we used to be restricted to 10 or 15.
“The melting point data from the Optim system has shown a good correlation with long term stability, and this is very valuable to us. The support we have had from Avacta has been excellent; they are very open and flexible and our work has really progressed.”
